Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study.
Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study.
复制标题
DOI：
10.1002/ijc.28022
复制
发表时间：
2013-07-15
影响因子：
6.4
通讯作者：
Silverman, Debra T.
中科院分区：
文献类型：
--
作者：
Daugherty, Sarah E.;Lacey, James V., Jr.;Pfeiffer, Ruth M.;Park, Yikyung;Hoover, Robert N.;Silverman, Debra T.
在许多国家，女性膀胱癌的发病率至少是男性的三分之一到四分之一。即使在考虑了已知的风险因素之后，这种性别差异的原因仍然无法解释。我们在NIH-AARP饮食与健康研究中对生殖因素和外源性激素的使用进行了全面评估，主要关注绝经期激素治疗的使用和女性膀胱癌的风险。在1995-1996年的基线问卷调查中，确定了201，492名女性的生殖和激素因素，这些女性被随访至2006年12月31日。在随访期间，诊断出651例膀胱癌。一部分妇女在1996-1997年的第二份调查表中提供了关于产妇保健疗法使用情况的详细资料。在这项分析中，127，361名女性被随访至2002年6月30日，并确定了198例膀胱癌病例。采用考克斯比例风险模型，以年龄作为时间指标，对吸烟状况、每日吸烟量和体重指数进行校正，以获得风险比（HR）。在经产女性（HR=0.76; 95% CI 0.62-0.93）和报告初潮年龄较晚（≥15岁）的女性（HR=0.57; 95% CI 0.39-0.84）中观察到风险降低。与未报告使用MHT的女性相比，报告曾使用雌激素和孕激素治疗的女性风险降低（HR=0.53; 95%CI：0.34-0.83）。仅雌激素使用者未观察到相关性（HR=0.82; 95% CI：0.58-1.15）。我们的研究结果表明，性激素在女性膀胱癌的病因学中起着假定的作用。
The incidence of bladder cancer among women is at least one third to one fourth that observed among men in many countries. Even after accounting for known risk factors, the reason for this gender disparity remains unexplained. We conducted a comprehensive evaluation of reproductive factors and exogenous hormone use with a primary focus on menopausal hormone therapy use and risk of bladder cancer in women in the NIH-AARP Diet and Health Study. Reproductive and hormonal factors were ascertained on the baseline questionnaire in 1995–1996 among 201,492 females who were followed until December 31, 2006. During follow-up, 651 cases of bladder cancer were diagnosed. A subset of women provided detailed information on use of MHT in a second questionnaire in 1996–1997. In this analysis, 127,361 females were followed through June 30, 2002 and 198 incident bladder cancer cases were identified. Cox proportional hazard models, adjusted for smoking status, cigarettes per day, and body mass index using age as the time metric, were used to obtain hazard ratios (HRs). A reduced risk was observed among parous women (HR=0.76; 95% CI 0.62–0.93) and women who reported late age at menarche (≥15 years) (HR=0.57; 95% CI 0.39–0.84). Women who reported ever using estrogen and progestin therapy had a decreased risk (HR=0.53; 95% CI: 0.34–0.83) compared to women who did not report MHT use. No association was observed for estrogen only users (HR=0.82; 95% CI: 0.58–1.15). Our results suggest a putative role for sex hormones in the etiology of bladder cancer among women.
登录
查看更多内容
影响因子：
2.3
作者：
Huang, An-Tsun;Kogevinas, Manolis;Silverman, Debra T.;Malats, Nuria;Rothman, Nathaniel;Tardon, Adonina;Serra, Consol;Garcia-Closas, Reina;Carrato, Alfredo;Cantor, Kenneth P.
通讯作者：
Cantor, Kenneth P.
影响因子：
5.4
作者：
Jain, MG;Rohan, TE;Howe, GR
通讯作者：
Howe, GR
影响因子：
11.2
作者：
Li CI;Nishi N;McDougall JA;Semmens EO;Sugiyama H;Soda M;Sakata R;Hayashi M;Kasagi F;Suyama A;Mabuchi K;Davis S;Kodama K;Kopecky KJ
通讯作者：
Kopecky KJ
影响因子：
4.5
作者：
Blakeman, PJ;Hilton, P;Bulmer, JN
通讯作者：
Bulmer, JN
影响因子：
8.4
作者：
Dietrich, K.;Demidenko, E.;Schned, A.;Zens, M. S.;Heaney, J.;Karagas, M. R.
通讯作者：
Karagas, M. R.